TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).

J Randolph Hecht et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.